Clinical Trial Update: Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan [Phase 3]

View source ↗

Summary

Phase 3 trial update on aflibercept as mono-therapy for center-involved diabetic macular edema in Taiwan; results focus on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Center-involved Diabetic Macular Edema
• Diabetic Macular Edema

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Taipei Veterans General Hospital, Taiwan | Conditions: Center-involved Diabetic Macular Edema | Phase 3 | Status: COMPLETED